Neos Therapeutics, Inc. (NEOS) financial statements (2022 and earlier)

Company profile

Business Address 2940 N. HIGHWAY 360
GRAND PRAIRIE, TX 75050
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments12,74412,67931,85024,89425,27630,25139,965
Cash and cash equivalents12,74412,67927,85816,83023,28425,75732,760
Short-term investments  3,9928,0641,9924,4947,205
Receivables20,38617,38520,78226,56328,87720,14423,222
Inventory, net of allowances, customer advances and progress billings8,4368,73010,21811,01011,67612,37411,276
Inventory8,4368,73010,21811,01011,67612,37411,276
Other current assets  2,904 1,7571,8112,555
Other undisclosed current assets2,4431,612 4,092   
Total current assets:44,00940,40665,75466,55967,58664,58077,018
Noncurrent Assets
Finance lease, right-of-use asset384      
Operating lease, right-of-use asset2,6552,7912,9203,0443,161  
Property, plant and equipment 6,6377,0147,3457,5177,6367,532
Intangible assets, net (including goodwill)11,07411,70812,13912,54313,18713,61914,016
Intangible assets, net (excluding goodwill)11,07411,70812,13912,54313,18713,61914,016
Other noncurrent assets1,0221,1471,2661,382304149149
Other undisclosed noncurrent assets5,440    3,2743,381
Total noncurrent assets:20,57522,28323,33924,31424,16924,67825,078
TOTAL ASSETS:64,58462,68989,09390,87391,75589,258102,096
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities39,67635,56843,58946,83844,39640,24042,670
Accounts payable8,4439,44613,0336,6506,5486,5568,552
Accrued liabilities31,23326,12230,55640,18837,84833,68434,118
Debt26,7925,2929,8101,5171,746 8,615
Other undisclosed current liabilities69320,00015,00015,00015,00016,978571
Total current liabilities:67,16160,86068,39963,35561,14257,21851,856
Noncurrent Liabilities
Long-term debt and lease obligation, including:13,7203,1823,3743,5853,789 43,266
Finance lease, liability258282307331355  
Operating lease, liability2,7412,9003,0673,2543,434  
Other undisclosed long-term debt and lease obligation10,721     43,266
Liabilities, other than long-term debt1,5141,9441,3851,2951,4191,5552,071
Other liabilities58154154160180182183
Derivative instruments and hedges, liabilities1,4561,7901,2311,1351,2391,3731,888
Other undisclosed noncurrent liabilities2,74112,87629,11528,76828,43332,0973,775
Total noncurrent liabilities:17,97518,00233,87433,64833,64133,65249,112
Total liabilities:85,13678,862102,27397,00394,78390,870100,968
Stockholders' equity
Stockholders' equity attributable to parent(20,552)(16,173)(13,180)(6,130)(3,028)(1,612)1,128
Common stock50505050505050
Treasury stock, value(352)(352)(352)(352)(352)(352)(352)
Additional paid in capital332,004331,472328,956328,056327,671327,035326,014
Accumulated other comprehensive income (loss)  11 1(1)
Accumulated deficit(352,254)(347,343)(341,835)(333,885)(330,397)(328,346)(324,583)
Total stockholders' equity:(20,552)(16,173)(13,180)(6,130)(3,028)(1,612)1,128
TOTAL LIABILITIES AND EQUITY:64,58462,68989,09390,87391,75589,258102,096

Income statement (P&L) ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Revenues12,53513,13314,49316,83217,54015,64314,634
Cost of revenue
(Cost of Goods and Services Sold)
(5,120)(5,878)(6,389)(7,181)(6,447)(5,099)(6,396)
Gross profit:7,4157,2558,1049,65111,09310,5448,238
Operating expenses(10,331)(10,130)(13,992)(11,366)(11,526)(12,990)(14,059)
Operating loss:(2,916)(2,875)(5,888)(1,715)(433)(2,446)(5,821)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
12(544)(25)276251670336
Interest and debt expense(2,005)(2,089)(2,037)(2,038)(1,869)(1,987)(2,115)
Loss from continuing operations before income taxes:(4,909)(5,508)(7,950)(3,477)(2,051)(3,763)(7,600)
Income tax expense(2)      
Other undisclosed loss from continuing operations   (11)   
Net loss available to common stockholders, diluted:(4,911)(5,508)(7,950)(3,488)(2,051)(3,763)(7,600)

Comprehensive Income ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Net loss:(4,911)(5,508)(7,950)(3,488)(2,051)(3,763)(7,600)
Comprehensive loss:(4,911)(5,508)(7,950)(3,488)(2,051)(3,763)(7,600)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (1) 1(1)2(1)
Comprehensive loss, net of tax, attributable to parent:(4,911)(5,509)(7,950)(3,487)(2,052)(3,761)(7,601)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: